ARDX — Ardelyx, Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 395
- Website: https://www.ardelyx.com
Latest SEC filings for ARDX
- 8-K — 2026-08-17
- SCHEDULE 13G/A — 2026-08-11
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- 8-K — 2026-07-02
- 8-K — 2026-06-17
- SCHEDULE 13G/A — 2026-05-15
- SCHEDULE 13G — 2026-05-12
- 8-K — 2026-04-30
- 10-Q — 2026-04-30
Latest ARDX news
- — Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm (GlobeNewswire Inc.)
- — ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX (GlobeNewswire Inc.)
- — ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & Korsinsky (prnewswire_financial)
- — ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law (prnewswire_all)
- — Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc. (GlobeNewswire Inc.)
- — ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law (GlobeNewswire Inc.)
- — Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm (GlobeNewswire Inc.)
- — ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt (prnewswire_financial)
- — ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses (prnewswire_financial)
- — ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX (GlobeNewswire Inc.)
Educational tool only — not investment advice.